Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)

NCT00550342 Phase 2 WITHDRAWN

The purpose of this study is to determine whether the approved drug, rituximab, is effective in the treatment of focal segmental glomerulosclerosis (FSGS)

Details

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase	Phase 2
Status	WITHDRAWN
Start date	2008-01
Completion	2009-12

Conditions

• Focal Segmental Glomerulosclerosis (FSGS)

Interventions

• rituximab

Primary outcomes

• The primary endpoint will be resolution of proteinuria defined as a Up/C ratio of <0.2. — One year

Countries

United States